Last updated on May 2018

Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain


Brief description of study

This study is to provide safety information of hemoporfin during the post-marketing period as required by China Food and Drug Administration (CFDA) regulations in order to identify any potential drug related treatment factors in the Chinese population, such as unknown/unexpected adverse reactions, the incidence of adverse reactions under the routine drug uses.

Clinical Study Identifier: NCT03181984

Contact Investigators or Research Sites near you

Start Over

Ke Wang

Peking University First Hospital
Beijing, China
  Connect »

Jining Tao

The 2nd Affiliated Hospital of Harbin Medical University
Harbin, China
  Connect »

Jining Tao

Affiliated Hospital of Hebei Medical College of traditional Chinese Medicine
Shijiazhuang, China
  Connect »

Jining Tao

Wuxi People's Hospital
Wuxi, China
  Connect »

Jining Tao

West China Hospital, Sichuan University
Chengdu, China
  Connect »

Jining Tao

PLA Army General Hospital
Beijing, China
  Connect »

Jining Tao

Shanghai Dermatology Hospital
Shanghai, China
  Connect »